Neuracle Science Technology
NS300
| Pipeline | NS300 |
|---|---|
| Summary | NS300 is a peptide drug candidate that binds to FAM19A5 and interferes with the binding of FAM19A5 to LRRC4B. Based on the hypothesis that interfering with the binding of FAM19A5 to LRRC4B, even not with antibodies, could restore synaptic connections and neuronal functions, we utilized biochemical research methods and artificial intelligence techniques using AlphaFold2/RosettaFold to learn that FAM19A5 binds to a contiguous 13-amino acid sequence of LRRC4B. A peptide composed of these 13 amino acids competitively bound to FAM19A5, inhibiting its binding to LRRC4B, and performed the same function as NS101 in neurons. We further analyzed the peptide with Schrödinger to identify the optimal amino acid sequence, which we named NS300. NS300 promoted synaptic binding in neurons in the same way as NS101, and we found that it restored vision, inhibited optic nerve death, and prevented retinal vascular loss in mouse diabetic retinopathy in the same way as NS101. |
Discovery of FAM19A5 binding peptide (NS300) based on amino acid sequence of FB site
Structural analysis of FAM19A5 & FB
Precise prediction of the exact amino acid sequence of FAM19A5-binding domains, using AI-based protein structure analysis
Structural analysis of FAM19A5 & FB
NS300 promotes synaptic coupling of neurons and shows equivalent efficacy to NS101 in animal models of diabetic retinopathy
NS300 recovers vision loss in diabetic retinopathy mouse model